TY - JOUR
T1 - Effects of COVID-19 on Pediatric Cancer Care
T2 - A Multicenter Study of 11 Middle Eastern Countries
AU - Elzembely, Mahmoud M.
AU - Al Rawas, Abdulhakim
AU - Al-Hebshi, Abdulqader
AU - Alhadi, Abdulrahman
AU - Ibrahim, Ahmed K.
AU - Zein, Amal Ahmed
AU - Ragab, Iman
AU - Alshamsi, Eman Taryam
AU - Dammag, Enas
AU - Gachi, Fatiha
AU - Zain, Gamal Hussien
AU - Mohammad, Hadeel Saleh
AU - Haddad, Hisham
AU - Boudiaf, Houda
AU - Alharbi, Ibrahim
AU - Sultan, Iyad
AU - Salami, Khadra Hasan
AU - Bayoumy, Mohamed S.
AU - Al-Mulla, Naima Ali
AU - Al Mashaikhi, Nawal
AU - Almajali, Rami Mohammed
AU - Farah, Roula
AU - Al Daama, Saad A.
AU - Ahmad, Salah
AU - Ragab, Seham M.
AU - Fadel, Shady H.
AU - Ahmed, Soha
AU - Al-Sweedan, Suleimman
AU - Abdelmabood, Suzy
AU - Kaleem, Waleed Khaled
AU - Madney, Youssef
N1 - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/10/12
Y1 - 2022/10/12
N2 - During the COVID-19 pandemic, major challenges are facing pediatric cancer centers regarding access to cancer centers, continuity of the anti-cancer therapy, hospital admission, and infection protection precautions. Pediatric oncologists actively treating children with cancer from 29 cancer centers at 11 countries were asked to answer a survey from May 2020 to August 2020 either directly or through the internet. COVID-19 pandemic affected the access to pediatric cancer care in the form of difficulty in reaching the center in 22 (75.9%) centers and affection of patients' flow in 21 (72.4%) centers. Health care professionals (HCP) were infected with COVID-19 in 20 (69%) surveyed centers. Eighteen centers (62%) modified the treatment guidelines. Care of follow-up patients was provided in-hospital in 8(27.6%) centers, through telemedicine in 10 (34.5%) centers, and just delayed in 11 (38%) centers. Pediatric oncologists had different expectations about the future effects of COVID-19 on pediatric cancer care. Seventy-six percent of pediatric oncologists think the COVID-19 pandemic will increase the use of telemedicine. Fifty-five percent of pediatric oncologists think if the COVID-19 pandemic persists, we will need to change chemotherapy protocols to less myelosuppressive ones. Collaborative studies are required to prioritize pediatric cancer management during COVID-19 era.
AB - During the COVID-19 pandemic, major challenges are facing pediatric cancer centers regarding access to cancer centers, continuity of the anti-cancer therapy, hospital admission, and infection protection precautions. Pediatric oncologists actively treating children with cancer from 29 cancer centers at 11 countries were asked to answer a survey from May 2020 to August 2020 either directly or through the internet. COVID-19 pandemic affected the access to pediatric cancer care in the form of difficulty in reaching the center in 22 (75.9%) centers and affection of patients' flow in 21 (72.4%) centers. Health care professionals (HCP) were infected with COVID-19 in 20 (69%) surveyed centers. Eighteen centers (62%) modified the treatment guidelines. Care of follow-up patients was provided in-hospital in 8(27.6%) centers, through telemedicine in 10 (34.5%) centers, and just delayed in 11 (38%) centers. Pediatric oncologists had different expectations about the future effects of COVID-19 on pediatric cancer care. Seventy-six percent of pediatric oncologists think the COVID-19 pandemic will increase the use of telemedicine. Fifty-five percent of pediatric oncologists think if the COVID-19 pandemic persists, we will need to change chemotherapy protocols to less myelosuppressive ones. Collaborative studies are required to prioritize pediatric cancer management during COVID-19 era.
KW - COVID-19
KW - middle eastern countries
KW - multicenter study
KW - pediatric oncology
KW - telemedicine
KW - COVID-19/epidemiology
KW - Telemedicine
KW - Humans
KW - Surveys and Questionnaires
KW - Child
KW - Neoplasms/epidemiology
KW - Pandemics/prevention & control
UR - http://www.scopus.com/inward/record.url?scp=85145641625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145641625&partnerID=8YFLogxK
U2 - 10.1097/mph.0000000000002564
DO - 10.1097/mph.0000000000002564
M3 - Article
C2 - 36219708
AN - SCOPUS:85145641625
SN - 1077-4114
VL - 45
SP - e87-e91
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
IS - 1
ER -